Rani Therapeutics Q3 net loss widens on higher R&D costs

Rani Therapeutics Holdings

09/11/2026 21:24

Overview
Biotherapeutics firm's Q3 contract revenue rose on Chugai collaboration, net loss widened yr/yr
Company accepted into FDA Emerging Technology Program for RaniPill platform
Company expects cash reserves to fund operations through end of 2027

Outlook
Company expects to fund operations at least through end of 2027
Company expects additional RT-114 Phase 1a data by end of 2026
Company plans to invest in manufacturing automation to support further clinical development

Result Drivers
R&D SPENDING - Higher research and development expenses driven by increased compensation, third-party services, and facility costs
ADMINISTRATIVE COSTS - General and administrative expenses rose due to higher third-party services and other costs

Company press release: ID:nGNX1B0MD0

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Loss
 
$8.81 mln
 
Q3 Operating Expenses
 
$10.93 mln
 
Q3 Loss From Operations
 
$9.22 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Rani Therapeutics Holdings, Inc is $5.50, about 905.9% above its November 6 closing price of $0.55

Reuters Recommended Reads
Nov 9 - CervoMed Q3 net loss narrows as R&D costs drop after completion of RewinD-LB trial
Nov 9 - Neurogene Q3 net loss widens on higher R&D and G&A costs
Nov 9 - Bicara Therapeutics Q3 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)